You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Nasopharyngeal cacinoma (NPC)

Showing 1 - 25 of 953
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Reveals Relationship Between gp42-IgG Epitopes and

Not yet recruiting
  • Nasopharyngeal Carcinoma
  • Epitope exploration
  • (no location specified)
Jul 16, 2023

Nasopharyngeal Carcinoma Trial in Fuzhou (without concurrent cisplatin chemo, with concurrent cisplatin chemo)

Not yet recruiting
  • Nasopharyngeal Carcinoma
  • without concurrent cisplatin chemotherapy
  • with concurrent cisplatin chemotherapy
  • Fuzhou, Fujian, China
    Department of radiation oncology, Fujian cancer hospital
Oct 18, 2023

Nasopharyngeal Carcinoma Trial in Zhongshan (Anrotinib plus Tirelizumab)

Recruiting
  • Nasopharyngeal Carcinoma
  • Anrotinib plus Tirelizumab
  • Zhongshan, Guangdong, China
    Zhongshan City People's Hospital
Jul 31, 2023

Nasopharyngeal Carcinoma Trial in Shanghai (Anti-EGFR and PD-1 inhibitor arm)

Recruiting
  • Nasopharyngeal Carcinoma
  • Anti-EGFR and PD-1 inhibitor arm
  • Shanghai, Shanghai, China
    Eye & ENT Hospital of Fudan University
Nov 26, 2023

Nasopharyngeal Carcinoma Trial in Xi'an (gemcitabine,nimotuzumab, toripalimab, gemcitabine, cisplatin)

Recruiting
  • Nasopharyngeal Carcinoma
  • gemcitabine,nimotuzumab, toripalimab
  • gemcitabine, cisplatin
  • Xi'an, Shaanxi, China
    Department of Radiation Oncology, Xijing Hospital, Fourth Milita
Sep 5, 2023

Nasopharyngeal Carcinoma Trial (Envafolimab and recombinant human endostatin combined with chemoradiotherapy)

Not yet recruiting
  • Nasopharyngeal Carcinoma
  • Envafolimab and recombinant human endostatin combined with chemoradiotherapy
  • (no location specified)
Sep 23, 2023

Advanced Nasopharyngeal Carcinoma Trial in Hangzhou (SBRT)

Recruiting
  • Advanced Nasopharyngeal Carcinoma
  • SBRT
  • Hangzhou, Zhejiang, China
    Zhejiang Cancer Hospital
Dec 5, 2022

Nasopharyngeal Carcinoma Trial in Guangzhou (Camrelizumab, Gemcitabine, Cisplatin)

Recruiting
  • Nasopharyngeal Carcinoma
  • Guangzhou, Guangdong, China
    Department of Nasopharyngeal Carcinoma, Sun Yat-sen University C
May 3, 2023

Nasopharyngeal Carcinoma Trial in Guangzhou (Dalpiciclib Isetionate Tablets, Camrelizumab)

Recruiting
  • Nasopharyngeal Carcinoma
  • Dalpiciclib Isetionate Tablets, Camrelizumab
  • Guangzhou, Guangdong, China
    Department of Nasopharyngeal Carcinoma, Sun Yat-sen University C
Feb 2, 2023

Nasopharyngeal Cancer, Epstein-Barr Virus Related Carcinoma Trial in Singapore (FDG-PET, Galium-68 DOTATATE)

Recruiting
  • Nasopharyngeal Cancer
  • Epstein-Barr Virus Related Carcinoma
  • FDG-PET
  • Galium-68 DOTATATE
  • Singapore, Singapore
    National Cancer Centre Singapore
Oct 13, 2022

Nasopharyngeal Cancer Trial in Shanghai (Toripalimab, Induction chemo and concurrent chemoradiation)

Recruiting
  • Nasopharyngeal Cancer
  • Toripalimab
  • Induction chemotherapy and concurrent chemoradiation
  • Shanghai, Shanghai, China
    Fudan Universtiy Shanghai Cancer Centre
Nov 25, 2022

Nasopharyngeal Carcinoma Trial in Hong Kong (Trans-oral magnifying endoscopy with NBI)

Recruiting
  • Nasopharyngeal Carcinoma
  • Trans-oral magnifying endoscopy with NBI
  • Hong Kong, Hong Kong
    Prince of Wales Hospital
Aug 15, 2022

Nasopharyngeal Carcinoma by AJCC V8 Stage Trial in Guanzhou (HLX07, HLX10, )

Not yet recruiting
  • Nasopharyngeal Carcinoma by AJCC V8 Stage
  • Guanzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
Aug 23, 2022

Nasopharyngeal Carcinoma, Intensity-Modulated Radiotherapy Trial in Zhongshan (Reduction CTVp1, Non-reduction CTVp1)

Recruiting
  • Nasopharyngeal Carcinoma
  • Intensity-Modulated Radiotherapy
  • Reduction CTVp1
  • Non-reduction CTVp1
  • Zhongshan, Guangdong, China
    Zhongshan City People's Hospital
Aug 8, 2023

Nasopharyngeal Carcinoma Trial in China (Endostatin and Capecitabine)

Recruiting
  • Nasopharyngeal Carcinoma
  • Endostatin and Capecitabine
  • Hangzhou, Zhejiang, China
  • +6 more
Aug 21, 2022

Nasopharyngeal Cancer, Epstein-Barr Virus Related Carcinoma Trial in Stanford (VK-2019)

Recruiting
  • Nasopharyngeal Cancer
  • Epstein-Barr Virus Related Carcinoma
  • Stanford, California
    Stanford University
Mar 31, 2022

Recurrent or Metastatic NPC Trial in Hong Kong (Axitinib, Avelumab)

Recruiting
  • Recurrent or Metastatic NPC
  • Hong Kong, Hong Kong
    Department of Clinical Oncology, Prince of Wales Hospital, The C
Jul 18, 2022

NPC Trial in Guangzhou (Sintilimab, IBI310)

Active, not recruiting
  • NPC
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
Oct 3, 2022

Nasopharyngeal Carcinoma Trial in Guangzhou (Apatinib, Camrelizumab, Chemotherapy (gemcitabine/ capecitabine/ docetaxel),

Not yet recruiting
  • Nasopharyngeal Carcinoma
  • Apatinib, Camrelizumab, Chemotherapy (gemcitabine/ capecitabine/ docetaxel)
  • +3 more
  • Guangzhou, Guangdong, China
    Department of Nasopharyngeal Carcinoma, Sun Yat-sen University C
Sep 17, 2022

Nasopharyngeal Carcinoma Trial in Guangzhou (BL-B01D1, capecitabine, gemcitabine)

Not yet recruiting
  • Nasopharyngeal Carcinoma
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
Oct 31, 2023

Locally Advanced Nasopharyngeal Carcinoma, Envafolimab, Induction Chemo Trial in Guangzhou (Envafolimab Plus Chemoradiotherapy)

Recruiting
  • Locally Advanced Nasopharyngeal Carcinoma
  • +3 more
  • Envafolimab Plus Chemoradiotherapy
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
Aug 9, 2022

Renal Cell Carcinoma, Nasopharyngeal Carcinoma, Non Hodgkin Lymphoma Trial in United States (PRO1160)

Not yet recruiting
  • Renal Cell Carcinoma
  • +2 more
  • Detroit, Michigan
  • +4 more
Jan 31, 2023

Verification of Harmonization of Plasma Epstein-Barr Virus DNA

Recruiting
  • Nasopharyngeal Carcinoma
  • Plasma EBV DNA qPCR test
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
Jul 3, 2022

Nasopharyngeal Carcinoma Trial in Guangzhou (MRI Scanning, Contrast-Enhanced Ultrasonography, Ultrasound-guided Lymph Node

Recruiting
  • Nasopharyngeal Carcinoma
  • MRI Scanning
  • +2 more
  • Guangzhou, Guangdong, China
    Sun Yat-Sen University Cancer Center
Jul 4, 2022

Nasopharyngeal Carcinoma, Nasopharyngeal Cancer Trial in Shanghai (Fluzoparib and Camrelizumab)

Recruiting
  • Nasopharyngeal Carcinoma
  • Nasopharyngeal Cancer
  • Fluzoparib and Camrelizumab
  • Shanghai, Shanghai, China
    Fudan Universtiy Shanghai Cancer Centre
Jun 4, 2022